The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
复制标题
皇家马斯登（Royal Marsden）的小肠腺癌的经验，该腺癌用长期的静脉输液5-氟尿嘧啶治疗。
DOI：
10.1038/bjc.1998.523
复制
发表时间：
1998-08
影响因子：
8.8
通讯作者：
Cunningham, D
中科院分区：
文献类型：
--
作者：
Crawley, C;Ross, P;Norman, A;Hill, A;Cunningham, D
本研究的目的是回顾以5-氟尿嘧啶（PVI 5-FU）为基础的长期静脉输注化疗在晚期小肠腺癌中的疗效。从胃肠科和医院数据库中检索了5年内在单一机构就诊的所有小肠恶性肿瘤患者的数据，并对这些病例进行了审查。8例晚期小肠腺癌患者接受了PVI 5 FU为基础的化疗。可评估患者的总有效率为37.5%（3/8）。中位总生存期为13个月（范围1-28），无进展生存期为7.8个月（范围0-15）。总体而言，治疗耐受性良好，并观察到症状获益。总之，PVI 5-FU在这种疾病中具有活性。在多中心随机研究中，应将其作为单药或联合方案（如表阿霉素/顺铂/PVI FU（ECF））的一部分进行评估。
The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range 0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre randomized study.